scholarly journals Efficacy and Mode of Action of Mesenchymal Stem Cells in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review

Biomedicines ◽  
2020 ◽  
Vol 8 (12) ◽  
pp. 570
Author(s):  
Cecilie Hoeeg ◽  
Sabina Frljak ◽  
Abbas Ali Qayyum ◽  
Bojan Vrtovec ◽  
Jens Kastrup ◽  
...  
Keyword(s):  
Systematic Review ◽  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Cardiac Function ◽  
Dilated Cardiomyopathy ◽  
Mode Of Action ◽  
Preclinical Studies ◽  
Gene And Protein Expression ◽  
Non Ischemic Dilated Cardiomyopathy

Non-ischemic dilated cardiomyopathy (NIDCM) constitutes one of the most common causes to non-ischemic heart failure. Despite treatment, the disease often progresses, causing severe morbidity and mortality, making novel treatment strategies necessary. Due to the regenerative actions of mesenchymal stem cells (MSCs), they have been proposed as a treatment for NIDCM. This systematic review aims to evaluate efficacy and mode of action (MoA) of MSC-based therapies in NIDCM. A systematic literature search was conducted in Medline (Pubmed) and Embase. A total of 27 studies were included (3 clinical trials and 24 preclinical studies). MSCs from different tissues and routes of delivery were reported, with bone marrow-derived MSCs and direct intramyocardial injections being the most frequent. All included clinical trials and 22 preclinical trials reported an improvement in cardiac function following MSC treatment. Furthermore, preclinical studies demonstrated alterations in tissue structure, gene, and protein expression patterns, primarily related to fibrosis and angiogenesis. Consequently, MSC treatment can improve cardiac function in NIDCM patients. The MoA underlying this effect involves anti-fibrosis, angiogenesis, immunomodulation, and anti-apoptosis, though these processes seem to be interdependent. These encouraging results calls for larger confirmatory clinical studies, as well as preclinical studies utilizing unbiased investigation of the potential MoA.

scholarly journals Adipose-derived mesenchymal stem cells preserve cardiac function via ANT-1 in dilated cardiomyopathy hamster model

2021 ◽  
Vol 18 ◽  
pp. 182-190
Author(s):  
Daisuke Mori ◽  
Shigeru Miyagawa ◽  
Takashi Kido ◽  
Hiroki Hata ◽  
Takayoshi Ueno ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cardiac Function ◽  
Dilated Cardiomyopathy ◽  
Hamster Model

scholarly journals Mesenchymal stem cells for sensorineural hearing loss: protocol for a systematic review of preclinical studies

2019 ◽  
Vol 8 (1) ◽  
Author(s):  
Kevin T. Chorath ◽  
Matthew J. Willis ◽  
Nicolas Morton-Gonzaba ◽  
Walter J. Humann ◽  
Alvaro Moreira
Keyword(s):  
Systematic Review ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Preclinical Studies

scholarly journals Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yunyu Zhao ◽  
Zhipeng Yan ◽  
Ying Liu ◽  
Yue Zhang ◽  
Jie Shi ◽  
...  
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Acute Lung Injury ◽  
Pulmonary Fibrosis ◽  
Lung Injury ◽  
Inflammatory Response ◽  
Lung Tissue ◽  
Preclinical Studies ◽  
Patient Prognosis

AbstractPulmonary fibrosis (PF) is a chronic, progressive, fibrotic interstitial disease of the lung with poor prognosis and without effective treatment currently. Data from previous coronavirus infections, such as the Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome, as well as current clinical evidence from the Coronavirus disease 2019 (COVID-19), support that SARS-CoV-2 infection may lead to PF, seriously impacting patient prognosis and quality of life. Therefore, effective prevention and treatment of PF will improve patient prognosis and reduce the overall social and economic burdens. Stem cells, especially mesenchymal stem cells (MSCs) have many great advantages, including migration to damaged lung tissue and secretion of various paracrine factors, thereby regulating the permeability of endothelial and epithelial cells, reducing inflammatory response, promoting tissue repair and inhibiting bacterial growth. Clinical trials of MSCs for the treatment of acute lung injury, PF and severe and critically ill COVID-19 are ongoing. The purpose of this study is to systematically review preclinical studies, explored the effectiveness of MSCs in the treatment of bleomycin (BLM)-induced pulmonary fibrosis and analyze the potential mechanism, combined with clinical trials of current MSCs for idiopathic pulmonary fibrosis (IPF) and COVID-19, so as to provide support for clinical research and transformation of MSCs. Searching PubMed and Embase (− 2021.4) identified a total of 36 preclinical studies of MSCs as treatment of BLM-induced acute lung injury and PF in rodent models. Most of the studies showed the MSCs treatment to reduce BLM-induced lung tissue inflammatory response, inflammatory cell infiltration, inflammatory cytokine expression, extracellular matrix production and collagen deposition, and to improve Ashcroft score. The results of present studies indicate that MSCs may serve as a potential therapeutic modality for the treatment of PF, including viral-induced PF and IPF.

scholarly journals Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated Cardiomyopathy

Circulation ◽  
2005 ◽  
Vol 112 (8) ◽  
pp. 1128-1135 ◽  
Author(s):  
Noritoshi Nagaya ◽  
Kenji Kangawa ◽  
Takefumi Itoh ◽  
Takashi Iwase ◽  
Shinsuke Murakami ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Cardiac Function ◽  
Dilated Cardiomyopathy ◽  
Rat Model

scholarly journals Mesenchymal stem cells for inflammatory airway disorders: promises and challenges

2019 ◽  
Vol 39 (1) ◽  
Author(s):  
Xing-Liang Fan ◽  
Zhao Zhang ◽  
Chui Yan Ma ◽  
Qing-Ling Fu
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Clinical Setting ◽  
Lung Diseases ◽  
Preclinical Studies ◽  
Immunomodulatory Effects ◽  
Paracrine Effects ◽  
Clinical Therapy

Abstract The regenerative and immunomodulatory characteristics of mesenchymal stem cells (MSCs) make them attractive in the treatment of many diseases. Although they have shown promising preclinical studies of immunomodulation and paracrine effects in inflammatory airway disorders and other lung diseases, there are still challenges that have to be overcome before MSCs can be safely, effectively, and routinely applied in the clinical setting. A good understanding of the roles and mechanisms of the MSC immunomodulatory effects will benefit the application of MSC-based clinical therapy. In this review, we summarize the promises and challenges of the preclinical and clinical trials of MSC therapies, aiming to better understand the role that MSCs play in attempt to treat inflammatory airway disorders.

Sign in / Sign up

Export Citation Format

Share Document